Abstract
Radiotherapy (RT) remains the mainstay of medulloblastoma treatment but its impact on neurocognitive outcome of young children is massive. In this age group, the main challenge is to limit the cost of cure by deferring, completely avoiding or at least reducing RT (field or dose) without jeopardizing survival. In the past, survival of young children with medulloblastoma was somewhat lower than in older children treated with standard craniospinal RT. Apart from the decrease of RT other causes can be discussed: differences in tumor biology, higher frequency of metastases, inclusion of others embryonal tumors such as atypical teratoid/rhabdoid tumor (ATRT) or embryonal tumor with multilayered rosettes (ETMR) with known worse prognosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
